| Literature DB >> 34758472 |
Koji Otani1, Toshio Watanabe2, Akira Higashimori1, Hidekazu Suzuki3, Takeshi Kamiya4, Akiko Shiotani5, Mitsushige Sugimoto6, Akihito Nagahara7, Shin Fukudo8, Satoshi Motoya9, Satoru Yamaguchi10, Qi Zhu11, Francis K L Chan12, Ki-Baik Hahm13, Maria Carla Tablante14, Varayu Prachayakul15, Murdani Abdullah16, Tiing Leong Ang17, Kazunari Murakami18.
Abstract
INTRODUCTION: The COVID-19 outbreak abruptly restricted gastrointestinal (GI) endoscopy services during the first wave of the pandemic. We aimed to assess the impact of COVID-19 on the practice of GI endoscopy in Asian countries.Entities:
Keywords: Asia; COVID-19; Endoscopy; Personal protective equipment; Severe acute respiratory syndrome coronavirus 2
Mesh:
Year: 2021 PMID: 34758472 PMCID: PMC8678234 DOI: 10.1159/000520287
Source DB: PubMed Journal: Digestion ISSN: 0012-2823 Impact factor: 3.216
Fig. 1Impact of the COVID-19 pandemic on the number of GI endoscopies. a The degree of the decrease in the number of screening or follow-up endoscopies compared to before the pandemic during and after the first wave. b The degree of the decrease in the number of therapeutic endoscopies compared to before the pandemic during and after the first wave. c The degree of the decrease in the number of urgent endoscopies (on call) compared to before the pandemic during and after the first wave. d The reason for the decrease in GI endoscopic procedures during the first wave. e The reason for the decrease in GI endoscopic procedures after the first wave. PPE, personal protective equipment; GI, gastrointestinal.
The decrease in the number of GI endoscopies and PPE used during endoscopic procedures by country in Asia
| Country | JPN | CHN | HKG | KOR | PHL | THA | IDN | SGP | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The degree of the decrease in the number of screening or follow-up endoscopies compared to before pandemic during the first wave, | ||||||||||||||
| Not decreased | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||||
| 1–25% | 8 (13.3) | 1 (3.8) | 0 (0.0) | 0 (0.0) | 2 (8.7) | 0 (0.0) | 3 (16.7) | 1 (11.1) | ||||||
| 26–50% | 14 (23.3) | 5 (19.2) | 3 (20.0) | 5 (71.4) | 0 (0.0) | 3 (37.5) | 5 (27.8) | 3 (33.3) | ||||||
| 51–75% | 22 (36.7) | 6 (23.1) | 5 (33.3) | 1 (14.3) | 11 (47.8) | 1 (12.5) | 9 (50.0) | 4 (44.4) | ||||||
| 76–99% | 9 (15.0) | 8 (30.8) | 6 (40.0) | 1 (14.3) | 8 (34.8) | 2 (25.0) | 1 (5.6) | 0 (0.0) | ||||||
| Closed (100) | 6 (10.0) | 6 (23.1) | 1 (6.7) | 0 (0.0) | 2 (8.7) | 2 (25.0) | 0 (0.0) | 1 (11.1) | ||||||
| The degree of the decrease in the number of screening or follow-up endoscopies compared to before pandemic after the first wave, | ||||||||||||||
| Not decreased | 11 (18.3) | 8 (30.8) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 5 (62.5) | 0 (0.0) | 3 (33.3) | ||||||
| 1–25% | 22 (36.7) | 7 (26.9) | 4 (26.7) | 5 (71.4) | 2 (8.7) | 2 (25.0) | 5 (27.8) | 3 (33.3) | ||||||
| 26–50% | 11 (18.3) | 9 (34.6) | 6 (40.0) | 0 (0.0) | 11 (47.8) | 0 (0.0) | 6 (33.3) | 2 (22.2) | ||||||
| 51–75% | 7 (11.7) | 2 (7.7) | 4 (26.7) | 1 (14.3) | 9 (39.1) | 1 (12.5) | 6 (33.3) | 1 (11.1) | ||||||
| 76–99% | 8 (13.3) | 0 (0.0) | 0 (0.0) | 1 (14.3) | 1 (4.3) | 0 (0.0) | 1 (5.6) | 0 (0.0) | ||||||
| Closed (100) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||||
| The degree of the decrease in the number of therapeutic endoscopies compared to before pandemic during the first wave, | ||||||||||||||
| Not decreased | 2 (3.3) | 1 (3.8) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (11.1) | 1 (11.1) | ||||||
| 1–25% | 19 (31.7) | 0 (0.0) | 4 (26.7) | 3 (42.9) | 2 (8.7) | 3 (37.5) | 3 (16.7) | 5 (55.6) | ||||||
| 26–50% | 16 (26.7) | 5 (19.2) | 3 (20.0) | 2 (28.6) | 3 (13.0) | 2 (25.0) | 6 (33.3) | 1 (11.1) | ||||||
| 51–75% | 10 (16.7) | 5 (19.2) | 3 (20.0) | 1 (14.3) | 13 (56.5) | 1 (12.5) | 4 (22.2) | 2 (22.2) | ||||||
| 76–99% | 9 (15.0) | 7 (26.9) | 4 (26.7) | 0 (0.0) | 3 (13.0) | 1 (12.5) | 3 (16.7) | 0 (0.0) | ||||||
| Closed (100) | 4 (6.7) | 8 (30.8) | 0 (0.0) | 1 (14.3) | 2 (8.7) | 1 (12.5) | 0 (0.0) | 0 (0.0) | ||||||
| The degree of the decrease in the number of therapeutic endoscopies compared to before pandemic after the first wave, | ||||||||||||||
| Not decreased | 23 (38.3) | 8 (30.8) | 3 (20.0) | 1 (14.3) | 1 (4.3) | 6 (75.0) | 2 (11.1) | 5 (55.6) | ||||||
| 1–25% | 17 (28.3) | 6 (23.1) | 7 (46.7) | 4 (57.1) | 3 (13.0) | 2 (25.0) | 5 (27.8) | 1 (11.1) | ||||||
| 26–50% | 6 (10.0) | 8 (30.8) | 3 (20.0) | 1 (14.3) | 9 (39.1) | 0 (0.0) | 6 (33.3) | 2 (22.2) | ||||||
| 51–75% | 5 (8.3) | 4 (15.4) | 1 (6.7) | 0 (0.0) | 8 (34.8) | 0 (0.0) | 3 (16.7) | 0 (0.0) | ||||||
| 76–99% | 9 (15.0) | 0 (0.0) | 1 (6.7) | 1 (14.3) | 2 (8.7) | 0 (0.0) | 2 (11.1) | 1 (11.1) | ||||||
| Closed (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||||
| The degree of the decrease in the number of urgent endoscopies (on call) compared to before pandemic during the first wave, | ||||||||||||||
| Not decreased | 21 (35.0) | 6 (23.1) | 10 (66.7) | 2 (28.6) | 2 (8.7) | 3 (37.5) | 1 (5.6) | 4 (44.4) | ||||||
| 1–25% | 11 (18.3) | 4 (15.4) | 1 (6.7) | 1 (14.3) | 2 (8.7) | 2 (25.0) | 6 (33.3) | 3 (33.3) | ||||||
| 26–50% | 10 (16.7) | 7 (26.9) | 1 (6.7) | 2 (28.6) | 5 (21.7) | 1 (12.5) | 7 (38.9) | 0 (0.0) | ||||||
| 51–75% | 6 (10.0) | 4 (15.4) | 1 (6.7) | 1 (14.3) | 9 (39.1) | 0 (0.0) | 2 (11.1) | 2 (22.2) | ||||||
| 76–99% | 5 (8.3) | 3 (11.5) | 0 (0.0) | 0 (0.0) | 3 (13.0) | 2 (25.0) | 0 (0.0) | 0 (0.0) | ||||||
| Closed (100) | 7 (11.7) | 2 (7.7) | 2 (13.3) | 1 (14.3) | 2 (8.7) | 0 (0.0) | 2 (11.1) | 0 (0.0) | ||||||
| The degree of the decrease in the number of urgent endoscopies (on call) compared to before pandemic after the first wave, | ||||||||||||||
| Not decreased | 28 (46.7) | 17 (65.4) | 12 (80.0) | 2 (28.6) | 2 (8.7) | 6 (75.0) | 2 (11.1) | 6 (66.7) | ||||||
| 1–25% | 14 (23.3) | 7 (26.9) | 0 (0.0) | 4 (57.1) | 6 (26.1) | 2 (25.0) | 6 (33.3) | 1 (11.1) | ||||||
| 26–50% | 4 (6.7) | 2 (7.7) | 1 (6.7) | 0 (0.0) | 6 (26.1) | 0 (0.0) | 6 (33.3) | 0 (0.0) | ||||||
| 51–75% | 3 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 7 (30.4) | 0 (0.0) | 3 (16.7) | 1 (11.1) | ||||||
| 76–99% | 10 (16.7) | 0 (0.0) | 1 (6.7) | 0 (0.0) | 2 (8.7) | 0 (0.0) | 0 (0.0) | 1 (11.1) | ||||||
| Closed (100) | 1 (1.7) | 0 (0.0) | 1 (6.7) | 1 (14.3) | 0 (0.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | ||||||
| PPE in short supply during the first wave, | ||||||||||||||
| None | 5 (8.3) | 8 (30.8) | 1 (6.7) | 2 (28.6) | 4 (17.4) | 0 (0.0) | 4 (22.2) | 7 (77.8) | ||||||
| Face shield | 34 (56.7) | 10 (38.5) | 8 (53.3) | 4 (57.1) | 7 (30.4) | 6 (75.0) | 12 (66.7) | 0 (0.0) | ||||||
| Goggle | 30 (50.0) | 9 (34.6) | 6 (40.0) | 3 (42.9) | 8 (34.8) | 6 (75.0) | 8 (44.4) | 0 (0.0) | ||||||
| Surgical mask | 46 (76.7) | 12 (46.2) | 9 (60.0) | 3 (42.9) | 9 (39.1) | 8 (100.0) | 9 (50.0) | 1 (11.1) | ||||||
| N95, FFP 2, or DS2 | 41 (68.3) | 17 (65.4) | 13 (86.7) | 3 (42.9) | 19 (82.6) | 7 (87.5) | 14 (77.8) | 2 (22.2) | ||||||
| Disposable gloves | 31 (51.7) | 5 (19.2) | 3 (20.0) | 3 (42.9) | 3 (13.0) | 4 (50.0) | 12 (66.7) | 0 (0.0) | ||||||
| Hairnet | 25 (41.7) | 3 (11.5) | 1 (6.7) | 1 (14.3) | 2 (8.7) | 4 (50.0) | 12 (66.7) | 0 (0.0) | ||||||
| Disposable gown | 50 (83.3) | 7 (26.9) | 12 (80.0) | 3 (42.9) | 15 (65.2) | 6 (75.0) | 12 (66.7) | 1 (11.1) | ||||||
| Shoe covers | 15 (25.0) | 4 (15.4) | 0 (0.0) | 2 (28.6) | 6 (26.1) | 5 (62.5) | 10 (55.6) | 0 (0.0) | ||||||
| PPE in short supply after the first wave, | ||||||||||||||
| None | 17 (28.3) | 19 (73.1) | 4 (26.7) | 3 (42.9) | 14 (60.9) | 4 (50.0) | 6 (33.3) | 9 (100.0) | ||||||
| Face shield | 18 (30.0) | 3 (11.5) | 5 (33.3) | 2 (28.6) | 2 (8.7) | 2 (25.0) | 11 (61.1) | 0 (0.0) | ||||||
| Goggle | 16 (26.7) | 2 (7.7) | 1 (6.7) | 1 (14.3) | 1 (4.3) | 2 (25.0) | 6 (33.3) | 0 (0.0) | ||||||
| Surgical mask | 26 (43.3) | 4 (15.4) | 3 (20.0) | 2 (28.6) | 2 (8.7) | 3 (37.5) | 10 (55.6) | 0 (0.0) | ||||||
| N95, FFP 2, or DS2 | 24 (40.0) | 7 (26.9) | 10 (66.7) | 4 (57.1) | 9 (39.1) | 1 (12.5) | 12 (66.7) | 0 (0.0) | ||||||
| Disposable gloves | 22 (36.7) | 1 (3.8) | 1 (6.7) | 3 (42.9) | 1 (4.3) | 3 (37.5) | 11 (61.1) | 0 (0.0) | ||||||
| Hairnet | 14 (23.3) | 1 (3.8) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 2 (25.0) | 9 (50.0) | 0 (0.0) | ||||||
| Disposable gown | 32 (53.3) | 3 (11.5) | 7 (46.7) | 3 (42.9) | 4 (17.4) | 3 (37.5) | 10 (55.6) | 0 (0.0) | ||||||
| Shoe covers | 8 (13.3) | 1 (3.8) | 0 (0.0) | 2 (28.6) | 1 (4.3) | 1 (12.5) | 9 (50.0) | 0 (0.0) | ||||||
| PPE used during endoscopic procedure for low-risk patients, | ||||||||||||||
| None | 1 (1.7) | 3 (11.5) | 0 (0.0) | 2 (28.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||||
| Face shield | 37 (61.7) | 11 (42.3) | 11 (73.3) | 3 (42.9) | 23 (100.0) | 6 (75.0) | 16 (88.9) | 8 (88.9) | ||||||
| Goggle | 45 (75.0) | 6 (23.1) | 8 (53.3) | 0 (0.0) | 18 (78.3) | 4 (50.0) | 7 (38.9) | 5 (55.6) | ||||||
| Surgical mask | 54 (90.0) | 17 (65.4) | 12 (80.0) | 3 (42.9) | 14 (60.9) | 6 (75.0) | 10 (55.6) | 0 (0.0) | ||||||
| N95, FFP 2, or DS2 | 15 (25.0) | 11 (42.3) | 7 (46.7) | 4 (57.1) | 22 (95.7) | 3 (37.5) | 18 (100.0) | 9 (100.0) | ||||||
| Disposable gloves | 59 (98.3) | 19 (73.1) | 13 (86.7) | 3 (42.9) | 23 (100.0) | 6 (75.0) | 16 (88.9) | 8 (88.9) | ||||||
| Hairnet | 32 (53.3) | 11 (42.3) | 7 (46.7) | 0 (0.0) | 22 (95.7) | 4 (50.0) | 14 (77.8) | 7 (77.8) | ||||||
| Disposable gown | 57 (95.0) | 13 (50.0) | 15 (100.0) | 4 (57.1) | 22 (95.7) | 7 (87.5) | 14 (77.8) | 9 (100.0) | ||||||
| Shoe covers | 8 (13.3) | 13 (50.0) | 1 (6.7) | 1 (14.3) | 18 (78.3) | 3 (37.5) | 10 (55.6) | 2 (22.2) | ||||||
| PPE using during endoscopic procedures for high-risk patients, | ||||||||||||||
| None | 2 (3.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||||
| Face shield | 42 (70.0) | 19 (73.1) | 15 (100.0) | 6 (85.7) | 22 (95.7) | 8 (100.0) | 17 (94.4) | 8 (88.9) | ||||||
| Goggle | 41 (68.3) | 23 (88.5) | 10 (66.7) | 3 (42.9) | 20 (87.0) | 7 (87.5) | 12 (66.7) | 5 (55.6) | ||||||
| Surgical mask | 30 (50.0) | 13 (50.0) | 3 (20.0) | 2 (28.6) | 14 (60.9) | 4 (50.0) | 14 (77.8) | 0 (0.0) | ||||||
| N95, FFP 2, or DS2 | 43 (71.7) | 25 (96.2) | 15 (100.0) | 6 (85.7) | 22 (95.7) | 7 (87.5) | 18 (100.0) | 9 (100.0) | ||||||
| Disposable gloves | 51 (85.0) | 24 (92.3) | 14 (93.3) | 7 (100.0) | 23 (100.0) | 7 (87.5) | 16 (88.9) | 9 (100.0) | ||||||
| Hairnet | 46 (76.7) | 19 (73.1) | 9 (60.0) | 2 (28.6) | 22 (95.7) | 7 (87.5) | 16 (88.9) | 6 (66.7) | ||||||
| Disposable gown | 50 (83.3) | 23 (88.5) | 15 (100.0) | 6 (85.7) | 22 (95.7) | 7 (87.5) | 16 (88.9) | 9 (100.0) | ||||||
| Shoe covers | 33 (55.0) | 22 (84.6) | 5 (33.3) | 2 (28.6) | 22 (95.7) | 7 (87.5) | 11 (61.1) | 3 (33.3) | ||||||
| Medical protecting coverall | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 0 (0.0) | ||||||
| Hazmat suits | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (8.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||||
| PAPR | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (8.7) | 0 (0.0) | 0 (0.0) | 3 (33.3) | ||||||
JPN, Japan; CHN, China; HKG, Hong Kong; KOR, South Korea; PHL, Philippines; THA, Thailand; IDN, Indonesia; SGP, Singapore; FFP, filtering face piece; DS, disposable solid; PAPR, powered air-purifying respirator; PPE, personal protective equipment; GI, gastrointestinal.
Fig. 2The indications for GI endoscopy during and after the first wave. ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound; ESD, endoscopic submucosal dissection; EMR, endoscopic mucosal resection; GI, gastrointestinal.
Fig. 3The way to assess the risk of SARS-CoV-2 infection before GI endoscopies and impact of the COVID-19 pandemic on the number of medical staff. a The way to assess the risk of SARS-CoV-2 infection before screening or follow-up endoscopies. b The way to assess the risk of SARS-CoV-2 infection before therapeutic endoscopies. c The way to assess the risk of SARS-CoV-2 infection before urgent endoscopies (on call). d–g The number of medical staff working in the endoscopic units during and after the first wave. d Doctor. e Nurse. f Technician. g Cleaning staff. h The experience of performing endoscopy for patients with a definite diagnosis of COVID-19. i COVID-19 case obviously infected through GI endoscopy. PCR, polymerase chain reaction; CT, computed tomography; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; GI, gastrointestinal.
Fig. 4GI symptoms with COVID-19 and GI diseases affected by the pandemic. a The experience of treating COVID-19 patients. b The frequency of GI symptoms in COVID-19 patients. c The GI symptoms of COVID-19 patients during the infected period (most common one). d The time that GI symptoms appeared (Before, before respiratory symptoms; At the same time, at the same time with respiratory symptoms; After, after respiratory symptoms). e The GI diseases exacerbated by the COVID-19 pandemic. f The delayed diagnosis of cancers due to postponed endoscopic procedure. g The types of cancer with a delayed diagnosis due to postponed endoscopic procedure. h The prescription delayed or canceled due to the COVID-19 pandemic. PPI, proton pump inhibitor; P-CAB, potassium-competitive acid blocker; GI, gastrointestinal.
Fig. 5Usage of PPE during endoscopic procedures. a PPE in short supply. b PPE used during endoscopic procedures. c The devices for preventing diffusion of aerosol droplets used during the endoscopic procedure. d The level of PPE during endoscopic procedures. e The excessive PPE. f The inadequate PPE. g Maintaining the present level of PPE during the endoscopic procedure after the COVID-19 pandemic. h The reasons for discontinuation of the present level of PPE after the COVID-19 pandemic. FFP, filtering face piece; DS, disposable solid; PAPR, powered air-purifying respirator; PPE, personal protective equipment.
Fig. 6Impact of the COVID-19 pandemic on education, research, and clinical practice. a Time of education affected by the COVID-19 pandemic compared to before the pandemic. b Time of basic research affected by the COVID-19 pandemic compared to before the pandemic. c Time of clinical research affected by the COVID-19 pandemic compared to before the pandemic. d Time of daily clinical practice affected by the COVID-19 pandemic compared to before the pandemic.